Newton, Massachusetts, November 25, 2024 /PRNewswire/ — Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering new cancer treatments, today announced that the company's senior management team will discuss Piper in a fireside chat on Tuesday. Sandler announced that he will be participating in the 36th Annual Healthcare Conference. , Dec. 3, 11:30 a.m. ET. New York, New York.
A live webcast of the Fireside Chat can be accessed under “Events and Presentations” in the Investor section of our website at https://investors.karyopharm.com/events-presentations and can be replayed after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company dedicated to pioneering novel cancer treatments, driven by a belief in the extraordinary strength and courage of cancer patients. Masu. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of carcinogenesis. Karyopharm's lead compound, XPOVIO® (selinexor), a first-in-class oral exportin 1 (XPO1) inhibitor, is approved in the United States and marketed by the company in three oncology indications. It has also received regulatory approval for various indications in a growing number of former U.S. territories and countries, including Europe, the United Kingdom (as NEXPOVIO®) and China. Karyopharm is a focused pipeline targeting multiple cancer indications with high unmet need, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). I have a line. To learn more about our people, science and pipeline, please visit www.karyopharm.com and follow us on LinkedIn and X (@Karyopharm).
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Other trademarks mentioned in this release are the property of their respective owners.
SOURCE Karyopharm Therapeutics Inc.
I want company news Have you been featured on PRNEWSWIRE.COM?
Over 440,000
newsroom and
influencer
9k+
digital media
outlet
Over 270,000
journalist
opt-in
